Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Hallura Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution means that each of the 2 pending office actions is being handled by a different examiner in a different technical group. Such a structure requires the prosecution team to adapt to multiple examiner styles despite the small size of the active portfolio.
CRAIGO, BAHAR ALAWI is the busiest examiner, with 1 pending office action. This 1 action represents half of the 2 pending office actions in the portfolio. Since there are 2 distinct examiners, CRAIGO, BAHAR ALAWI has the same workload as the other examiner involved in the Biotechnology & Pharmaceuticals filings. The involvement of 2 distinct art units for only 2 pending office actions suggests a diverse range of subject matter. Practitioners must navigate the specific requirements of 2 distinct examiners across these different units. The 1 pending office action under CRAIGO, BAHAR ALAWI is a significant part of the overall prosecution strategy for Hallura Ltd.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18438500 | CROSS-LINKED POLYCARBOXYLATED POLYSACCHARIDES AND METHODS OF USE THEREOF | CRAIGO, BAHAR ALAWI | 26d overdue |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18438500 | CROSS-LINKED POLYCARBOXYLATED POLYSACCHARIDES AND METHODS OF USE THEREOF | CRAIGO, BAHAR ALAWI | 1699 | §103§112DP | Final Rejection | 26d overdue | Pending | Feb 11, 2024 |
| 18286630 | COMPOSITIONS COMPRISING CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | KRISHNAN, GANAPATHY | 1693 | §103DP | Non-Final OA | — | Pending | Oct 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial